Abelcet

Name: Abelcet

Dosing & Uses

Dosing Form & Strengths

injectable, lipid complex

  • 5mg/mL

Systemic Fungal Infection

Indicated for invasive fungal infection refractory to conventional amphotericin B desoxycholate therapy or when renal impairment or unacceptable toxicity precludes use conventional amphotericin B

5 mg/kg IV qDay; infuse IV at rate of 2.5 mg/kg/hr  

Renal Impairment

CrCl

Other Indications & Uses

Activity shown in vitro for Aspergillus and Candida species

Activity shown in animal models for Cryptococcus sp, Coccidioidomyces sp, Histoplasma sp, and Blastomyces sp

Dosing Form & Strengths

injectable, lipid complex

  • 5mg/mL

Systemic Fungal Infection

Indicated for invasive fungal infection refractory to conventional amphotericin B desoxycholate therapy or when renal impairment or unacceptable toxicity precludes use conventional amphotericin B

As adults; 5 mg/kg IV qDay; infuse IV at rate of 2.5 mg/kg/hr  

Renal Impairment

CrCl

Other Indications & Uses

Activity shown in vitro for Aspergillus and Candida species

Activity shown in animal models for Cryptococcus sp, Coccidioidomyces sp, Histoplasma sp, and Blastomyces sp

Adverse Effects

>10%

Chills (18%)

Fever (14%)

Multiple organ failure (11%)

Serum creatinine increased (11%)

1-10%

Nausea (9%)

Hypotension (8%)

Respiratory Failure (8%)

Vomiting (8%)

Dyspnea (7%)

Sepsis (7%)

Diarrhea (6%)

Headache (6%)

Heart Arrest (6%)

Hypertension (5%)

Hypokalemia (5%)

Infection (5%)

Kidney Failure (5%)

Pain (5%)

Thrombocytopenia (5%)

Abdominal Pain (4%)

Anemia (4%)

Bilirubinemia (4%)

Gastrointestinal Hemorrhage (4%)

Leukopenia (4%)

Rash (4%)

Respiratory Disorder (4%)

Chest Pain (3%)

Nausea (3%)

Pregnancy & Lactation

Pregnancy Category: B

Lactation: Unknown whether distributed in breast milk, caution advised

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Administration

IV Incompatibilities

Solution: NaCl solutions or electrolyte solutions

IV Compatibilities

Solution: Dextrose solutions

Y-site: anidulafungin

IV Preparation

Shake vial gently until no yellow sediment visible at bottom

Withdraw dose from vial(s) into 1 or more 20 mL syringes using 18-gauge needle

Remove needle from syringe and attach 5-micron filter needle provided; 1 filter may be used for up to 4 vials

Insert filter needle into D5W IV bag of appropriate volume for dose and empty contents

Final concentration should not exceed 1 mg/mL; concentration of 2 mg/mL may be appropriate for children or fluid restricted patients

Do not use NaCl or electrolyte-containing fluids

Do not admix with other drugs or electrolytes

Do not use if precipitate or foreign matter present

IV Administration

Administer using separate infusion line; if an existing IV line is used, flush with D5W before infusion

Do not use inline filter during administration

Infusion rate: 2.5 mg/kg/hr

Prior to infusion initiation, gently shake IV container of diluted drug until contents are thoroughly mixed; infusion container should then be shaken every 2 hr if infusion time >2 hr

Do not mix with 0.9% NaCl or infuse in same IV line as other drugs

Storage

Prior to admixture, store refrigerated at 36-46°F (2- 8°C) and protected from light

Admixed with D5W, stable up to 48 hr when refrigerated at 36-46°F (2- 8°C) or up to 6 hr at room temp

Do not freeze

Patient Handout

Print without Office InfoPrint with Office Info
(web3)